- Trials with a EudraCT protocol (703)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
703 result(s) found for: Chronic inflammation.
Displaying page 1 of 36.
EudraCT Number: 2011-004936-75 | Sponsor Protocol Number: EVOLUTION | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
Full Title: An Evaluation of Losmapimod in patients with Chronic Obstructive Pulmonary Disease (COPD) with systemic inflammation stratified using fibrinogen (EVOLUTION) | |||||||||||||
Medical condition: The trial team will be looking at patients with Chronic Obstructive Pulmonary Disease and how inflammation affects them. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005909-19 | Sponsor Protocol Number: PAW002 | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:The University of Dundee | |||||||||||||
Full Title: Does extra fine HFA-BDP suppress small airways inflammation in COPD? | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000179-38 | Sponsor Protocol Number: ESR-21-21168 | Start Date*: 2022-04-28 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003077-42 | Sponsor Protocol Number: CE01-204 | Start Date*: 2015-02-06 | |||||||||||
Sponsor Name:Imperial College, London | |||||||||||||
Full Title: A single-centre, double-blind, randomised, placebo-controlled crossover study to evaluate the effect of solithromycin on airway inflammation in male and female patients with chronic obstructive pul... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003184-31 | Sponsor Protocol Number: Hx-CD20-408 | Start Date*: 2007-05-31 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive... | |||||||||||||
Medical condition: Moderate to severe stage of Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005389-39 | Sponsor Protocol Number: D2340C00011 | Start Date*: 2012-03-12 | |||||||||||
Sponsor Name:ASTRAZENECA | |||||||||||||
Full Title: A phase-II, double-blind, placebo-controlled, randomised, parallelgroup, multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice d... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003551-32 | Sponsor Protocol Number: ISS-U1111-1188-8695 | Start Date*: 2017-11-01 | |||||||||||
Sponsor Name:Hospital of South West Jutland | |||||||||||||
Full Title: Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease in obese subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003747-75 | Sponsor Protocol Number: EC07/90250 | Start Date*: 2008-04-21 | |||||||||||
Sponsor Name:Servei Pneumologia. Hospital Universitari Son Dureta | |||||||||||||
Full Title: EFECTOS ANTIINFLAMATORIOS DE LA OXIGENOTERAPIA DOMICILIARIA EN PACIENTES CON ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA ANTIINFLAMMATORY EFFECTS OF DOMICILIARY OXYGENTHERAPY IN PATIENTS WITH CHRONIC O... | |||||||||||||
Medical condition: Pacientes con enfermedad pulmonar obstructiva crónica e hipoxemia (Stable chronic obstructive pulmonary disease with hypoxemia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000331-41 | Sponsor Protocol Number: CHDR1430 | Start Date*: 2016-03-22 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers | |||||||||||||
Medical condition: none, this is a study on healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003103-39 | Sponsor Protocol Number: AR003 | Start Date*: 2007-04-19 | ||||||||||||||||
Sponsor Name:University of Glasgow & Greater Glasgow Health Board | ||||||||||||||||||
Full Title: Effect of statins on asthma control and airway inflammation in smokers with asthma | ||||||||||||||||||
Medical condition: Chronic Asthma (smokers),COPD. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004853-59 | Sponsor Protocol Number: EX6018-4758 | Start Date*: 2021-08-16 | ||||||||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||||||||||||
Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation | ||||||||||||||||||||||||||||
Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004869-18 | Sponsor Protocol Number: 030547 | Start Date*: 2008-07-03 | ||||||||||||||||||||||||||
Sponsor Name:UHB NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin defi... | ||||||||||||||||||||||||||||
Medical condition: The medical condition is emphysema and will be investigated in subjects with alpha 1-antitrypsin deficiency. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-000480-41 | Sponsor Protocol Number: FARM6AS8AW | Start Date*: 2008-05-27 | |||||||||||
Sponsor Name:UNIVERSITA' CAMPUS BIOMEDICO | |||||||||||||
Full Title: Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid. | |||||||||||||
Medical condition: Ocular cicatricial pemphigoid (OCP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000919-24 | Sponsor Protocol Number: 0671 | Start Date*: 2018-08-13 | ||||||||||||||||
Sponsor Name:University of Leicester | ||||||||||||||||||
Full Title: A randomised placebo-controlled trial of anti-ST2 in COPD (COPD-ST2OP) | ||||||||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000582-13 | Sponsor Protocol Number: RO-2455-402-RD | Start Date*: 2012-03-05 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study ... | |||||||||||||
Medical condition: severe chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005475-86 | Sponsor Protocol Number: 7356 | Start Date*: 2015-05-27 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease. | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) in patients who are considered to be at a higher risk of Coronary Artery Disease (CAD), myocardial infarction, and excess mortality. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005429-26 | Sponsor Protocol Number: CHDR2135 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: Immunological characterization of TLR-7 mediated inflammation and complement activation after prolonged Imiquimod exposure in healthy volunteers | |||||||||||||
Medical condition: Inflammation / Complement activation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020818-28 | Sponsor Protocol Number: 10.0086 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:St George's, University of London | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled trial of metformin in chronic obstructive pulmonary disease (COPD) exacerbations: a pilot study | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000841-12 | Sponsor Protocol Number: 215.1364 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) is characterised by airflow limitation and bronchial inflammation. Clinically, COPD is characterised by progressive dyspnoea on exertion and intermitten... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000868-95 | Sponsor Protocol Number: DvitKOL01022011 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Hvidovre Hospital | |||||||||||||
Full Title: Vitamin D and COPD A randomised, doubble-blind, placebo-controlled trial of the effect of vitamin D on withdrawal from pulmonary rehabilitation and exercise endurance | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
